{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093278","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.992379+00:00","generated_at":"2026-05-31T11:18:18.584238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nuvalent reports $658M cash, FDA breakthrough therapy for two candidates, net loss $57.2M in Q2","bullets":["Cash, equivalents and securities $658.0M as of June 30, 2024; operating runway into 2027.","Net loss $57.2M for Q2 2024; R&D expense $49.2M, G&A $16.0M.","FDA breakthrough therapy designation for zidesamtinib (ROS1) and NVL-655 (ALK).","Phase 2 enrollment ongoing for ALKOVE-1 (NVL-655) and ARROS-1 (zidesamtinib) with registrational intent; ESMO updates September 14.","Initiated HEROEX-1 Phase 1a/1b trial for NVL-330 in HER2-altered NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093278","json":"https://secwatch.observer/filing/0000950170-24-093278.json","markdown":"https://secwatch.observer/filing/0000950170-24-093278.md","text":"https://secwatch.observer/filing/0000950170-24-093278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024093278/0000950170-24-093278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024093278/nuvl-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:18:18.584238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}